



Autifony Therapeutics shortlisted in top five biotech SMEs in Europe by EuropaBio

London, UK – 01 Sept 2014 - Autofony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been selected by EuropaBio as one of the top five biotech SMEs in Europe, who will compete to win the 5th annual Most Innovative EU Biotech SME Award.

The top five candidates for this year’s EuropaBio Most Innovative EU Biotech SME award- which first began in 2010 - were selected from across the EU and operating in all sectors of biotechnology.

The annual EuropaBio award ceremony will take place during the European Biotech Week on October 8th in Brussels. The award has gained strong support and recognition as the main event amongst policy makers and the biotech business community alike, for outlining the issues faced by innovative SMEs operating in Europe such as intellectual property protection, access to finance and the general innovation climate in Europe. As well as this, the award aims to showcase some of the most outstanding examples of how biotechnology is of real benefit to society in areas as diverse as healthcare, agriculture, and industrial processes.

Dr Charles Large, Chief Executive Officer of Autofony commented: “We are delighted to have been selected for the top five shortlist of EuropaBio’s Most Innovative EU Biotech SME award. It shows recognition of Autofony’s pioneering approach to addressing areas of significant unmet medical need in hearing disorders and also in schizophrenia.”

- ENDS -

About Autofony Therapeutics Ltd

Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The company is focused on the development of high value, novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia. Autofony Therapeutics is funded by SV Life Sciences, Imperial Innovations, Pfizer Venture Investments, International Biotechnology Trust PLC and UCL Business. www.autifony.com

For more information, please contact:

Autifony

Dr Charles Large, Chief Executive Officer

E: charles.large@autifony.com

Instinctif Partners

Sue Charles, Tim Watson, Gemma Howe

T: +44 (0) 20 7866 7860

E: Autifony@instinctif.com